vs
EXACT SCIENCES CORP（EXAS）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Rithm Capital Corp.的1.1倍（$878.4M vs $828.2M），Rithm Capital Corp.净利率更高（13.2% vs -9.8%，领先23.0%），Rithm Capital Corp.同比增速更快（508.5% vs 23.1%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -17.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
EXAS vs RITM — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$828.2M
营收增速更快
RITM
高出485.4%
23.1%
净利率更高
RITM
高出23.0%
-9.8%
两年增速更快
EXAS
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $828.2M |
| 净利润 | $-86.0M | $109.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 29.9% |
| 净利率 | -9.8% | 13.2% |
| 营收同比 | 23.1% | 508.5% |
| 净利润同比 | 90.1% | 27.7% |
| 每股收益（稀释后） | $-0.45 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $878.4M | $1.5B | ||
| Q3 25 | $850.7M | $1.1B | ||
| Q2 25 | $811.1M | $1.2B | ||
| Q1 25 | $706.8M | $768.4M | ||
| Q4 24 | $713.4M | $2.1B | ||
| Q3 24 | $708.7M | $619.5M | ||
| Q2 24 | $699.3M | $1.2B |
净利润EXASRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $-86.0M | $85.0M | ||
| Q3 25 | $-19.6M | $221.5M | ||
| Q2 25 | $-1.2M | $311.7M | ||
| Q1 25 | $-101.2M | $78.8M | ||
| Q4 24 | $-864.6M | $290.2M | ||
| Q3 24 | $-38.2M | $121.7M | ||
| Q2 24 | $-15.8M | $235.6M |
毛利率EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASRITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | -9.4% | 13.8% | ||
| Q3 25 | -3.0% | 21.4% | ||
| Q2 25 | -0.3% | 25.2% | ||
| Q1 25 | -13.6% | 7.4% | ||
| Q4 24 | -122.8% | 23.8% | ||
| Q3 24 | -5.6% | 7.3% | ||
| Q2 24 | -3.8% | 23.6% |
净利率EXASRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | -9.8% | 5.7% | ||
| Q3 25 | -2.3% | 20.0% | ||
| Q2 25 | -0.1% | 25.6% | ||
| Q1 25 | -14.3% | 10.3% | ||
| Q4 24 | -121.2% | 14.0% | ||
| Q3 24 | -5.4% | 19.7% | ||
| Q2 24 | -2.3% | 19.2% |
每股收益（稀释后）EXASRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-0.45 | $0.09 | ||
| Q3 25 | $-0.10 | $0.35 | ||
| Q2 25 | $-0.01 | $0.53 | ||
| Q1 25 | $-0.54 | $0.07 | ||
| Q4 24 | $-4.69 | $0.50 | ||
| Q3 24 | $-0.21 | $0.20 | ||
| Q2 24 | $-0.09 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $9.1B |
| 总资产 | $5.9B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | $964.7M | $1.8B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $858.4M | $1.6B | ||
| Q1 25 | $786.2M | $1.5B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $1.0B | $1.6B | ||
| Q2 24 | $946.8M | $1.2B |
总债务EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益EXASRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $2.4B | $8.4B | ||
| Q3 25 | $2.5B | $8.5B | ||
| Q2 25 | $2.5B | $7.9B | ||
| Q1 25 | $2.4B | $7.8B | ||
| Q4 24 | $2.4B | $7.8B | ||
| Q3 24 | $3.2B | $7.7B | ||
| Q2 24 | $3.2B | $7.3B |
总资产EXASRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $5.9B | $53.1B | ||
| Q3 25 | $5.9B | $47.2B | ||
| Q2 25 | $5.8B | $44.3B | ||
| Q1 25 | $5.7B | $45.3B | ||
| Q4 24 | $5.9B | $46.0B | ||
| Q3 24 | $6.7B | $42.3B | ||
| Q2 24 | $6.7B | $42.0B |
负债/权益比EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $-114.6M | ||
| Q3 25 | $219.9M | $-2.0B | ||
| Q2 25 | $89.0M | $-557.1M | ||
| Q1 25 | $30.8M | $1.4B | ||
| Q4 24 | $47.1M | $-1.8B | ||
| Q3 24 | $138.7M | $768.1M | ||
| Q2 24 | $107.1M | $-55.7M |
自由现金流EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — |
自由现金流率EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — |
资本支出强度EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — |
现金转化率EXASRITM
| Q1 26 | — | — | ||
| Q4 25 | — | -1.35× | ||
| Q3 25 | — | -9.22× | ||
| Q2 25 | — | -1.79× | ||
| Q1 25 | — | 18.03× | ||
| Q4 24 | — | -6.04× | ||
| Q3 24 | — | 6.31× | ||
| Q2 24 | — | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
